Can we improve the outcome of pregnancies with low serum PAPP-A in the first trimester?
- Title
- Can we improve the outcome of pregnancies with low serum PAPP-A in the first trimester?
- Creator
- Tsibizova V.; Al-Sannan B.; Fedorova A.; Govorov I.; Meyyazhagan A.; Di Renzo G.C.
- Description
- Low birth weight is associated with various complications, and recent findings rely on the fact that micronized progesterone supplementation leads to improved birth weight, which is crucial for addressing concerns related to fetal growth. Objective: This study aimed to assess the impact of micronized progesterone (VMP4) supplementation on pregnancies with low serum pregnancy-associated plasma protein-A (PAPP-A) multiples of the median (MoM) values during first-trimester screening. Methods: Out of 8933 patients evaluated, 116 pregnant women with low PAPP-A concentrations in their blood and no fetal chromosomal anomalies (CAs) were included. Three groups were formed: group 1 received VMP4 from 11 to 16weeks (29 women, 25%), group 2 received VMP4 from 11 to 36weeks (25 women, 21.5%), and group 3 (62 women, 53.5%) served as controls without receiving progesterone. Results: Results indicated that group 3 had higher rates of complications, including miscarriages (16.37%), preterm delivery (17.8%), and fetal developmental abnormalities (19.4%). Birthweight variations were elevated in pregnancies without progesterone, contrasting with lower variations in VMP4 groups. Group 2, receiving VMP4 until 36weeks, reported the lowest incidence of abortion and preterm birth (PB), along with the highest mean birth weight. Conclusions: The conclusion suggests that 200 mg per day of VMP4 up to 36weeks of supplementation led to fewer placental-related complications in women with very low PAPP-A at first-trimester screening (0.399 MoM). By reporting lower rates of miscarriages, PBs, and fetal developmental abnormalities in the micronized progesterone-treated groups, the study suggests a potential reduction in complications. 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
- Source
- Journal of Maternal-Fetal and Neonatal Medicine, Vol-37, No. 1
- Date
- 2024-01-01
- Publisher
- Taylor and Francis Ltd.
- Subject
- first-trimester screening; micronized vaginal progesterone; PAPP-A; Pregnancy; preterm birth
- Coverage
- Tsibizova V., Almazov National Medical Research Centre, Saint Petersburg, Russian Federation, PREIS International School, Firenze, Italy; Al-Sannan B., Obstetrics and Gynecology Department, Faculty of Medicine, University of Kuwait, Kuwait City, Kuwait; Fedorova A., Leningrad Region Hospital, Saint Petersburg, Russian Federation; Govorov I., Almazov National Medical Research Centre, Saint Petersburg, Russian Federation; Meyyazhagan A., PREIS International School, Firenze, Italy, Department of Life Sciences, CHRIST (Deemed to be University), Bengaluru, India, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy; Di Renzo G.C., PREIS International School, Firenze, Italy, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy, Department of Obstetrics, Gynecology and Perinatal Medicine, First Moscow Medical University, Sechenov University, Moscow, Russian Federation
- Rights
- All Open Access; Hybrid Gold Open Access
- Relation
- ISSN: 14767058; PubMed ID: 38503546; CODEN: JMNMA
- Format
- Online
- Language
- English
- Type
- Article
Collection
Citation
Tsibizova V.; Al-Sannan B.; Fedorova A.; Govorov I.; Meyyazhagan A.; Di Renzo G.C., “Can we improve the outcome of pregnancies with low serum PAPP-A in the first trimester?,” CHRIST (Deemed To Be University) Institutional Repository, accessed February 25, 2025, https://archives.christuniversity.in/items/show/13682.